Revance Therapeutics Inc. (RVNC)
3.65
0.00 (0.00%)
At close: Feb 05, 2025, 3:59 PM
Revance Therapeutics Balance Sheet Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
| Cash & Equivalents | 137.33M | 108.97M | 110.62M | 333.56M | 171.16M | 73.26M | 282.9M | 63.5M | 201.62M | 171.03M | 3.91M | 4.08M | 29.62M |
| Short-Term Investments | 116.59M | 231.74M | 114.45M | 102.95M | 118.95M | 102.56M | n/a | 122.03M | 50.69M | n/a | n/a | n/a | n/a |
| Long-Term Investments | 6.87M | 6.05M | 5.05M | 3.44M | 730K | 730K | 580K | 580K | 1.75M | n/a | n/a | n/a | n/a |
| Other Long-Term Assets | 32.7M | 35.24M | 13.75M | 4.78M | 1.67M | 3.25M | 658K | 500K | 400K | 464K | 3.52M | 1.04M | 1.37M |
| Receivables | 27.68M | 11.34M | 3.35M | 1.83M | n/a | 27M | 48K | 6.03M | 158K | 300K | 225K | 75K | n/a |
| Inventory | 45.58M | 18.32M | 10.15M | 5.88M | n/a | 1.00 | 1.00 | 978K | 1.24M | 1.16M | 606K | 1.17M | n/a |
| Other Current Assets | 11.7M | 4.36M | 15.09M | 11.56M | 12.97M | 10.22M | 1.82M | 1.14M | 1.5M | 1.4M | 675K | 1.25M | 423K |
| Total Current Assets | 338.87M | 374.73M | 246.12M | 450M | 296.6M | 207.92M | 285.21M | 192.69M | 253.96M | 172.73M | 4.81M | 5.41M | 30.12M |
| Property-Plant & Equipment | 90.21M | 67.75M | 69M | 47.13M | 41.29M | 14.45M | 9.25M | 10.59M | 19.71M | 19.27M | 14.31M | 6.98M | 8.44M |
| Goodwill & Intangibles | 9.81M | 104.18M | 202.3M | 218.31M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Total Long-Term Assets | 139.59M | 207.17M | 285.05M | 270.22M | 43.69M | 18.43M | 10.49M | 11.66M | 21.86M | 19.74M | 17.83M | 8.02M | 9.81M |
| Total Assets | 478.45M | 581.9M | 531.16M | 720.22M | 340.29M | 226.35M | 295.7M | 204.36M | 275.82M | 192.47M | 22.64M | 13.42M | 39.93M |
| Account Payables | 13.81M | 4.55M | 10.6M | 12.66M | 8.01M | 8.43M | 6.8M | 3.75M | 2.66M | 3.15M | 5.53M | 1.8M | 777K |
| Deferred Revenue | 10.74M | 6.87M | 9.36M | 7.85M | 7.91M | 8.59M | 11.52M | 11.76M | 5.55M | 3.7M | 83K | 5.56M | 500K |
| Short-Term Debt | 10.85M | 9.82M | 9.49M | 8.87M | 3.47M | n/a | 1.87M | 3.48M | 3.13M | 2.94M | 27.75M | 95.45M | 4.55M |
| Other Current Liabilities | 53.82M | 54.45M | 37.83M | 31.58M | 21.59M | 14.95M | 12.22M | 12.42M | 6.25M | 4.14M | 19.09M | 20.68M | 3.03M |
| Total Current Liabilities | 89.22M | 75.68M | 67.29M | 60.96M | 40.98M | 31.97M | 20.9M | 19.65M | 12.04M | 10.24M | 47.56M | 117.94M | 8.86M |
| Long-Term Debt | 467.58M | 413.56M | 319.77M | 207.67M | 25.87M | n/a | n/a | n/a | n/a | n/a | 2.63M | 11M | 64.44M |
| Other Long-Term Liabilities | 2.83M | 1.49M | 1.49M | n/a | n/a | 6.07M | 5.95M | 7.64M | 10.53M | 5.86M | 130M | 101.22M | 112.12M |
| Total Long-Term Liabilities | 540.83M | 493.62M | 395.4M | 284.97M | 73.82M | 48.76M | 5.95M | 7.64M | 10.53M | 5.86M | 132.63M | 112.22M | 186.56M |
| Total Liabilities | 630.06M | 569.3M | 462.69M | 345.93M | 114.8M | 80.73M | 26.85M | 27.29M | 22.57M | 16.1M | 180.19M | 230.15M | 195.41M |
| Total Debt | 478.43M | 418.47M | 324.51M | 212.11M | 29.34M | n/a | 1.87M | 5.35M | 8.48M | 3.54M | 25.5M | 106.45M | 68.99M |
| Common Stock | 88K | 82K | 72K | 69K | 52K | 37K | 37K | 29K | 28K | 24K | 3.36M | n/a | n/a |
| Retained Earnings | -2.08B | -1.75B | -1.4B | -1.13B | -844.2M | -684.77M | -542.17M | -421.54M | -332.27M | -258.8M | -195.88M | -218.33M | -160.07M |
| Comprehensive Income | 14K | -374K | -18K | n/a | 3K | -8K | -13.53M | -45K | -40K | -9.91M | -8.19M | -6.36M | -4.6M |
| Shareholders Equity | -151.6M | 12.6M | 68.47M | 374.29M | 225.49M | 145.62M | 268.85M | 177.07M | 253.25M | 176.37M | -157.55M | -216.73M | -155.48M |
| Total Investments | 123.46M | 231.74M | 114.45M | 102.95M | 118.95M | 102.56M | 580K | 122.03M | 52.44M | n/a | n/a | n/a | n/a |